近年来，一种被称为抗体偶联药物（Antibody-Drug Conjugate, ADC）的新型抗癌药在临床实践中不断取得突破进展，使其在全球创新药领域迅速崛起。ADC 是一种什么样的药物？它为何能成为抗癌的新希望呢？

Boehringer Ingelheim is pumping funds into the still-hot antibody-drug conjugate space, committing 27 million Swiss francs ...

CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s ...

近几年，抗体-药物偶联物（Antibody-Drug Conjugate，ADC）已成为发展最为迅猛的抗肿瘤药物赛道之一。在介绍许多新型 ADC 时，常常强调其具备高载荷、高药物与抗体比率、可裂解连接子等一系列显著优势。然而，大部分肿瘤医师并未系统学习过 ADC 研发相关技术，对于这类药物的介绍往往一知半解。在 ADC ...

Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated ...

你是否听说过ADC药物？这种被称为‘魔法子弹’的抗癌新药正在改变癌症治疗的未来。2025年，科伦博泰生物将迎来商业化元年，其核心产品陆续获批上市，标志着国产ADC药物从‘跟跑’迈向‘并跑’。本文将带您深入了解这一领域的创新进展和未来潜力。

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

迈威生物 (688062.SH)，一家全产业链布局的创新型生物制药公司， 宣布将于当地时间 2025 年 4 月 25-30 日在美国芝加哥举行的 2025 年美国癌症研究协会 (AACR) 年会，以壁报形式公布 6 项研究成果 。

Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding ...